市场调查报告书
商品编码
1471183
高内容筛检市场:按产品、应用和最终用户划分 - 2024-2030 年全球预测High Content Screening Market by Product (Accessories, Consumables, Instruments), Application (Explorative Screening, Neurobiology, Oncology), End User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
高内容筛检市场规模预计到2023年为9.0359亿美元,预计到2024年将达到100095万美元,到2030年将达到191719万美元,复合年增长率为11.34%。
高内涵筛检(HCS) 是一种用于生物研究和药物发现的强大且多功能的技术,专注于细胞内复杂生物过程的定量分析。这种方法结合了高解析度显微镜、自动影像分析和复杂的软体,能够在细胞和亚细胞层面同时分析多个生化和型态参数。疾病的日益复杂性和对更有效药物的需求不断增长,增加了对 HCS 的需求。慢性病的增加以及药物发现和药物开发活动的进步正在推动 HCS 的采用。随着焦点转向个人化医疗,对能够分析单一细胞对药物反应的技术的需求日益增长。 HCS 透过评估患者来源的细胞来促进这一点,从而有助于制定更有针对性的治疗方法。然而,HCS 实验产生的大量资料需要先进的分析工具和强大的计算能力,从而导致资料管理和解释的复杂性。此外,很难将 HCS 系统与现有实验室工作流程整合并确保与其他技术的兼容性,并且没有标准化的通讯协定来比较不同平台和实验室的临床结果。然而,主要企业正在探索在 HCS 中使用 AI/ML 来改变资料分析,从而更聪明、更快速地解释复杂的资料集,并为药物发现开闢新的可能性。 3D细胞培养模型在HCS实验中的使用也显示出巨大的潜力。
主要市场统计 | |
---|---|
基准年[2023] | 90359万美元 |
预测年份 [2024] | 10.95亿美元 |
预测年份 [2030] | 1,917.19百万美元 |
复合年增长率(%) | 11.34% |
产品设备对先进自动化和影像处理能力的需求日益增长
高内涵筛检系统的附件是设计用于增强或支援主设备功能的辅助组件。这包括成像板、样品架和流体系统,可自动处理试剂和样品。消耗品是 HCS 过程中使用的需要定期更换的物品。此类别包括试剂、检测套件、微孔盘和其他执行高内涵筛检检测所需的材料。消耗品对于 HCS 实验的持续运作至关重要,因为它们直接影响所收集资料的品质和可靠性。微孔盘是多孔孔盘,通常由聚苯乙烯或聚丙烯製成,允许以紧凑且高效的形式同时测试多个样品和条件。试剂和检测试剂套件是 HCS 中的关键消耗品,旨在实现各种生物标的和活性的检测、定量和分析。这些消耗品包括专为特定检测量身定制的萤光染料、抗体、基材和缓衝液。该设备包括自动显微镜、影像细胞仪和用于执行筛检过程的整合 HCS 平台。这些仪器能够处理大量样品并获取高解析度影像以进行后续分析。细胞成像和分析系统将先进的显微镜与自动影像撷取、处理和分析功能整合在一起。流式细胞仪分析液体中生物颗粒通过至少一个雷射时的物理和化学特性。与高内涵筛检相关的服务包括系统安装、培训、维护和维修支持,以及检测开发和优化的咨询服务。此外,CRO(委外研发机构)提供 HCS 作为服务,使他们无需内部设备或专业知识即可利用该技术。软体是 HCS 流程的基础,使您能够控制设备、管理资料并分析结果。高内涵筛检软体包括影像分析程式、资料视觉化工具、统计分析套件等。解释 HCS 系统产生的大量资料,并将原始影像转化为有意义的生物学见解。
应用癌症研究固有的复杂性以及有效癌症治疗快速发展的需求正在推动 HCS 的采用。
探索性筛检涉及高通量寻找具有新颖生物相互作用和潜在治疗效果的化合物。 HCS 透过允许针对多个细胞模型筛检大量化合物库,促进新标靶的识别。 HCS 可以提供详细的多参数资料,使得根据细胞反应选择有希望的候选化合物的过程更加细緻,并已成为早期药物发现的基本步骤。在神经生物学中,HCS 用于阐明复杂的神经元过程,例如神经发生、突触形成和神经元连接。这使得研究人员能够筛检潜在的神经保护和神经毒性化合物,研究细胞层面的疾病病理学,并评估与神经系统疾病相关的遗传因素。在肿瘤学中,HCS 广泛用于抗癌药物的鑑定和检验。 HCS 有助于分析各种状态的癌细胞,包括它们对药物治疗的反应,有助于了解癌细胞的增殖、迁移、侵袭和凋亡。此技术可以分析细胞形状、大小和生物标记表达等多个参数,在评估癌细胞异质性和肿瘤组织的复杂环境方面特别有价值。标靶验证是药物开发平臺中的关键阶段,HCS 在确认新标靶的相关性和特异性方面发挥关键作用。透过提供对标靶修饰的细胞和分子反应的高品质表型分析,HCS 可以帮助早期消除安全性不佳或治疗相关性不足的标靶。在毒理学中,HCS 用于早期筛检化合物的细胞毒性作用。 HCS 提供对药物引起的毒性的详细评估,包括细胞层面的作用机制,例如粒线体功能障碍、DNA 损伤和氧化压力。此应用对于化妆品行业的药物安全评估、环境毒性评估和测试至关重要,确保只有安全的化合物才能进入临床试验。
区域洞察
以美国和加拿大为中心的美洲地区在全球 HCS 市场中占有重要地位。该地区的主导地位是由大型製药公司、尖端研究机构和大量医疗保健支出的存在所推动的。美国是生物医学研究和药物发现领域的领先国家,非常注重技术创新。美国已提交了大量 HCS 技术专利申请,反映出动态的研究环境和生命科学领域的巨大投资。 FDA 对推进药物发现过程的支持将进一步刺激技术的采用。药物发现中对高通量技术的需求以及支持创新医疗保健解决方案的法律规范推动了 HCS 在欧洲的采用。英国、德国和法国等国家走在前列,在生命科学和研究基础建设上投入大量资金。 MEA 地区前景广阔,对先进诊断和治疗研究的兴趣日益浓厚,这表明 HCS 技术市场正在快速成长。在快速扩张的製药和生物技术产业(尤其是中国、日本和印度)的推动下,亚太地区正在成为充满活力的高内涵筛检(HCS) 技术中心。中国处于利用 HCS 技术进行药物发现和毒性研究的前沿。日本是精准医学和再生医学的先驱,利用 HCS 进行干细胞研究和药物开发。印度已明显转向复杂的研发,重点在于效率和成本效益。
FPNV定位矩阵
FPNV定位矩阵对于评估高内容筛检市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对高内容筛检市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争力评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1. 高内容筛检市场的市场规模与预测为何?
2.在高内涵筛检市场的预测期间内,有哪些产品、细分市场、应用和领域需要考虑投资?
3. 高内容筛检市场的技术趋势和法规结构是什么?
4.高内涵筛检市场主要厂商的市场占有率为何?
5.进入高内涵筛检市场的合适型态和策略手段是什么?
[187 Pages Report] The High Content Screening Market size was estimated at USD 903.59 million in 2023 and expected to reach USD 1,000.95 million in 2024, at a CAGR 11.34% to reach USD 1,917.19 million by 2030.
High content screening (HCS) is a powerful and versatile technology used in biological research and drug discovery, emphasizing the quantitative analysis of complex biological processes within cells. This approach combines high-resolution microscopy, automated image analysis, and sophisticated software to enable the simultaneous analysis of multiple biochemical and morphological parameters at the cellular and subcellular levels. The growing complexity of diseases and the increasing need for more effective drugs drive the need for HCS. The growing incidences of chronic diseases and a need for advancing drug discovery and development activities have propelled the adoption of HCS. As the focus shifts towards personalized medicine, there is a growing need for technologies that can analyze individual cellular responses to drugs. HCS facilitates this by enabling the assessment of patient-derived cells, thus contributing to more tailored therapeutic approaches. However, the vast amount of data generated by HCS experiments requires sophisticated analysis tools and substantial computational power, posing complexities in data management and interpretation. Furthermore, integrating HCS systems with existing laboratory workflows and ensuring compatibility with other technologies can be challenging, and the lack of standardized protocols makes it difficult to compare clinical results across different platforms and laboratories. However, key players are exploring the utilization of AI/ML in HCS to transform data analysis, enabling more sophisticated and faster interpretation of complex datasets, thus providing new possibilities in drug discovery. The use of 3D cell culture models in HCS experiments also represents a significant opportunity.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 903.59 million |
Estimated Year [2024] | USD 1,000.95 million |
Forecast Year [2030] | USD 1,917.19 million |
CAGR (%) | 11.34% |
Product: Growing need for the advanced automation and imaging capabilities of instruments
Accessories for high content screening systems are supplementary components designed to enhance or support the functionality of the primary instruments. These can include imaging plates, sample holders, and fluidics systems that enable the automated handling of reagents and samples. Consumables are items that are used up during the HCS process and need regular replacement. This category includes reagents, assay kits, microplates, and other materials essential for conducting high content screening assays. Consumables are vital for the ongoing operation of HCS experiments, as they directly impact the quality and reliability of the data collected. Microplates are multi-well plates, typically made from polystyrene or polypropylene, which allow for the simultaneous testing of multiple samples or conditions in a compact and efficient format. Reagents and assay kits are critical consumables in HCS, designed to enable the detection, quantification, and analysis of various biological targets and activities. These consumables include fluorescent dyes, antibodies, substrates, and buffer solutions tailored for specific assays. Instruments encompass automated microscopes, image cytometers, and integrated HCS platforms that execute the screening process. These instruments are capable of handling large volumes of samples and acquiring high-resolution images for subsequent analysis. Cell imaging and analysis systems integrate advanced microscopy with automated image acquisition, processing, and analysis capabilities. Flow cytometers analyze the physical and chemical characteristics of biological particles in a fluid as they pass through at least one laser. Services related to high content screening include support for system installation, training, maintenance, and repair, as well as consulting services for assay development and optimization. Additionally, contract research organizations (CROs) offer HCS as a service, providing access to this technology without the need for in-house instruments and expertise. Software is fundamental to the HCS process, allowing for the control of instruments, management of data, and analysis of results. High content screening software includes image analysis programs, data visualization tools, and statistical analysis packages. It interprets the vast amounts of data generated by HCS systems, turning raw images into meaningful biological insights.
Application: Inherent complexity of oncology studies critical need for rapid advancement in effective cancer therapies driving adoption of HCS
Explorative screening involves the high-throughput search for novel biological interactions or compounds with potential therapeutic effects. Here, HCS facilitates the identification of new targets by enabling the screening of vast libraries of compounds against multiple cellular models. Its ability to provide detailed, multiparametric data allows for a more nuanced selection process of promising candidates based on cellular responses, making it a fundamental step in early-stage drug discovery. In neurobiology, HCS is employed to dissect complex neuronal processes, including neurogenesis, synaptogenesis, and neural connectivity. It allows researchers to screen potential neuroprotective or neurotoxic compounds, study disease pathology at a cellular level, and evaluate genetic factors involved in neurological disorders. Oncology utilizes HCS extensively for the identification and validation of anti-cancer drugs. By facilitating the analysis of cancer cells in various conditions, including response to drug treatments, HCS helps in understanding cancer cell proliferation, migration, invasion, and apoptosis. The technology's capability to analyze multiple parameters, such as cell shape, size, and biomarker expression, is particularly valuable in assessing the heterogeneity of tumor cells and the complex environment of tumor tissues. Target validation is a crucial phase in the drug development pipeline where HCS plays a vital role in confirming the relevance and specificity of novel targets. Through high-content, phenotypic characterization of cellular and molecular responses to target modulation, HCS aids in the early elimination of targets with undesirable safety profiles or insufficient therapeutic relevance. In toxicology, HCS is employed for early-stage screening of compounds for cytotoxic effects. It provides a detailed assessment of drug-induced toxicity, including mechanisms of action at the cellular level, such as mitochondrial dysfunction, DNA damage, and oxidative stress. This application is critical for pharmaceutical safety assessments, environmental toxicity evaluations, and cosmetic industry testing, ensuring that only safe compounds proceed to clinical trials.
Regional Insights
The Americas, predominantly led by the U.S. and Canada, hold a significant presence in the global HCS market. The region's dominance is fueled by the presence of leading pharmaceutical companies, cutting-edge research institutions, and substantial healthcare expenditure. The United States stands out as a key nation in biomedical research and drug discovery, with a strong emphasis on innovation. The country has seen numerous patents filed in HCS technology, reflecting a dynamic research environment and a substantial investment in life sciences. The FDA's support for advancing drug discovery processes further stimulates technological adoption. The adoption of HCS in Europe is driven by the need for high-throughput technologies in drug discovery and the strong regulatory framework supporting innovative healthcare solutions. Countries such as the UK, Germany, and France are at the forefront, witnessing considerable investment in life sciences and research infrastructure. The MEA region shows promise with an increasing interest in advanced diagnostics and therapeutic research, indicating a burgeoning market for HCS technologies. The APAC region is emerging as a vibrant hub for high content screening (HCS) technologies, driven by rapidly expanding pharmaceutical and biotechnology sectors, particularly in China, Japan, and India. China is at the forefront of leveraging HCS technologies for drug discovery and toxicology studies. Japan pioneers precision and regenerative medicine, utilizing HCS in stem cell research and pharmaceutical development. In India, there is a visible shift towards sophisticated R&D practices, with an increasing emphasis on efficiency and cost-effectiveness, which is propelling the need for HCS solutions.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the High Content Screening Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the High Content Screening Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the High Content Screening Market, highlighting leading vendors and their innovative profiles. These include Advanced Solutions, Inc., Agilent Technologies, Inc., Aurora Biomed Inc., Axxam S.p.A, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Charles River Laboratories International, Inc., Corning Incorporated, Creative Biolabs., Danaher Corporation, Evident Corporation, GE Healthcare, Genedata AG, Hamamatsu Photonics K.K., Merck KGaA, Ncardia Services B.V., Nikon Instruments Inc., Perkinelmer, Inc., Sartorius AG, Shimadzu Scientific Instruments, SPT Labtech Ltd., Tecan Trading AG, Thermo Fisher Scientific Inc., Yokogawa Electric Corporation, and Zeiss Group.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the High Content Screening Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the High Content Screening Market?
3. What are the technology trends and regulatory frameworks in the High Content Screening Market?
4. What is the market share of the leading vendors in the High Content Screening Market?
5. Which modes and strategic moves are suitable for entering the High Content Screening Market?